Brett Matthew  Hall net worth and biography

Brett Hall Biography and Net Worth

Chief Scientific Officer of Immuneering

Dr. Hall has served as our Chief Scientific Officer since November  2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., a privately held biotechnology services company from January  2019 until December  2021. Prior to that, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC, a privately held biotechnology company, from July  2015 until May  2018, and as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July  2014 until July  2015, before transitioning to executive discovery roles in biotechnology. From November  2008 until July 2014, Dr. Hall served in roles of increasing responsibility at Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant® and Imbruvica® through clinical development. Dr. Hall has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall’s career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.

What is Brett Matthew Hall's net worth?

The estimated net worth of Brett Matthew Hall is at least $1.91 million as of January 15th, 2026. Dr. Hall owns 376,496 shares of Immuneering stock worth more than $1,910,341 as of May 6th. This net worth evaluation does not reflect any other investments that Dr. Hall may own. Learn More about Brett Matthew Hall's net worth.

How do I contact Brett Matthew Hall?

The corporate mailing address for Dr. Hall and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Brett Matthew Hall's contact information.

Has Brett Matthew Hall been buying or selling shares of Immuneering?

Brett Matthew Hall has not been actively trading shares of Immuneering over the course of the past ninety days. Most recently, on Thursday, January 15th, Brett Matthew Hall bought 2,298 shares of Immuneering stock. The stock was acquired at an average cost of $4.57 per share, with a total value of $10,501.86. Following the completion of the transaction, the insider now directly owns 376,496 shares of the company's stock, valued at $1,720,586.72. Learn More on Brett Matthew Hall's trading history.

Who are Immuneering's active insiders?

Immuneering's insider roster includes Peter Feinberg (Director), Brett Hall (Chief Scientific Officer), Diana Hausman (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.

Are insiders buying or selling shares of Immuneering?

In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.

Information on this page was last updated on 1/16/2026.

Brett Matthew Hall Insider Trading History at Immuneering

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2026Buy2,298$4.57$10,501.86376,496View SEC Filing Icon  
6/23/2025Buy6,007$2.43$14,597.01359,318View SEC Filing Icon  
6/20/2025Buy7,415$2.70$20,020.50353,311View SEC Filing Icon  
5/25/2022Buy2,551$3.92$9,999.92332,685View SEC Filing Icon  
See Full Table

Brett Matthew Hall Buying and Selling Activity at Immuneering

This chart shows Brett Matthew Hall's buying and selling at Immuneering by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immuneering Company Overview

Immuneering logo
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.15
Low: $5.06
High: $5.40

50 Day Range

MA: $5.32
Low: $4.78
High: $6.13

2 Week Range

Now: $5.15
Low: $1.10
High: $10.08

Volume

615,911 shs

Average Volume

1,387,192 shs

Market Capitalization

$332.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37